Brief: Nurix Extends Gilead Collaboration For Oncology Program
05/10/2026 12:03
BRIEF-Nurix Extends Gilead Collaboration For Oncology Program Oct 5 (Reuters) - Nurix Therapeutics, Inc. NRIX.O:
NURIX THERAPEUTICS ANNOUNCES SECOND RESEARCH TERM EXTENSION FOR ONCOLOGY PROGRAM UNDER COLLABORATION WITH GILEAD SCIENCES
NURIX - CO AND GILEAD EXTEND ONCOLOGY PROGRAM RESEARCH TERM BY TWO YEARS
NURIX - RETAINS CO-DEVELOPMENT AND 50/50 PROFIT SHARING OPTIONS ON TWO U.S. PROGRAMS
NURIX - TO RECEIVE $10 MILLION RESEARCH TERM EXTENSION FEE
NURIX - ELIGIBLE FOR UP TO $1.30 BILLION IN TOTAL PAYMENTS AS OF MAY 31, 2026
NURIX - ELIGIBLE FOR MID-SINGLE-DIGIT TO LOW-TEENS PERCENTAGE TIERED ROYALTIES
Source text: ID:nGNX4n7JFl
Further company coverage: NRIX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nurix Therapeutics
See all newsNurix Therapeutics Q3 swings to profit on Roche collaboration
Brief: Nurix Extends Gilead Collaboration For Oncology Program
Commercialize Potential Best-In-Class Btk Degrader Bexobrutideg Across Malignant Hematology, Immunology And Neurology
Nurix Therapeutics Q2 revenue falls sharply, net loss widens; strikes up to $2.3 bln collab with Roche
U.S. RESEARCH ROUNDUP- Datadog, Jabil, Prologis